Indian contract research, development, and manufacturing organization (CRDMO) Aragen Life Sciences has received a $100 million investment from Quadria Capital.
The deal grants Quadria a minority stake in Aragen, valuing the company at approximately $1.4 billion, and includes a fresh capital infusion with additional share sales from existing investors.
The funding will enable Aragen to expand its capabilities and infrastructure, addressing growing demand for outsourcing services from innovators in the USA and Europe. Quadria joins Goldman Sachs as the second strategic investor in the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze